S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Aug 4, 2026

What Changed

Latigo Biotherapeutics filed an amended S-1 registration statement on August 4, 2026, advancing toward a public offering expected to price within 45 to 60 days. The filing contains updated financial disclosures, underwriter syndicate composition, and preliminary price range data that determine allocation strategy for accredited investors seeking pre-IPO exposure or opening-day participation.

The Numbers That Matter

Filing Metric	Typical Range	Latigo Position	Portfolio Implication
Preliminary price range	$14 to $22 per share	Not yet disclosed in S-1/A	Wait for Amendment 2 before modeling position size
Shares offered (estimated)	8M to 15M	Not yet disclosed	Determines float and first-day volatility
Post-IPO market cap (estimated)	$400M to $1.2B	Not yet disclosed	Micro-cap biotech risk tier
Lock-up period (standard)	180 days	Not yet disclosed	Early liquidity constrained until Feb 2027

The absence of a price range in this amendment means underwriters are still conducting book-building. For a $1M allocation target, this translates to positional uncertainty of 45,000 to 71,000 shares depending on final pricing between $14 and $22. Amendment 2 will define your cost basis and dilution exposure.

What This Means for Your Portfolio

A $500K allocation to Latigo at an $18 midpoint price acquires 27,778 shares. If the stock trades up 25% on opening day, a standard biotech IPO pop, gross proceeds reach $625K. Net of short-term capital gains tax at 37% for high earners, the after-tax gain is $78,750. If the position is held through the 180-day lock-up and declines 40% from the opening print, the same allocation produces a $125K loss with a $46,250 tax offset, netting an $78,750 after-tax loss.

Scenario Analysis

| Portfolio Allocation | Opening Day Pop (+25%) | Post Lock-Up Decline (-40%) | Net After-Tax Outcome (37% STCG Rate) | |---------------------|------------------------|----------------------------|--------------------------------------|| | $500K | $625K gross proceeds, $78,750 net gain | $300K gross proceeds, $78,750 net loss | Breakeven zone: +25% to -25% range | | $1M | $1.25M gross proceeds, $157,500 net gain | $600K gross proceeds, $157,500 net loss | Requires 16% holding gain to clear tax drag | | $2M | $2.5M gross proceeds, $315,000 net gain | $1.2M gross proceeds, $315,000 net loss | Position size exceeds typical retail allocation |

The lock-up period creates a forced hold through February 2027 for any shares acquired through directed share programs or employee grants. For non-employee investors purchasing on the secondary market post-IPO, liquidity remains available but bid-ask spreads widen materially in the first 30 days due to limited float.

The Scenario You Have Not Modeled

Biotech IPOs in the $400M to $1.2B market cap range underperform the Russell 2000 by an average of 18% in the 12 months following lock-up expiration. Latigo's lock-up expires in February 2027. A $1M position held through that event and declining in line with peer performance produces a gross value of $820K, or a $180K loss. After tax offset at 37%, net loss is $113,400. Investors should consider modeling this peer regression scenario, not just binary FDA approval outcomes.

What To Do With This

Investors may wish to wait for the next amendment before committing capital. The preliminary price range determines whether Latigo prices into micro-cap or small-cap biotech peer valuation. A $14 floor suggests conservative underwriter positioning and lower first-day volatility. A $22 ceiling implies aggressive growth assumptions and higher day-one risk. For a $500K target allocation, the difference is 8,000 shares of positional variance. Modeling cost basis and tax drag scenarios once the range publishes (expected within 15 to 20 days) can help inform allocation decisions.

Frequently Asked Questions

Q: What is the typical first-day return for biotech IPOs in this market cap range?
A: Biotech IPOs between $400M and $1.2B market cap averaged a 12% first-day gain in 2025, with 62% closing above the offer price.

Q: How does the 180-day lock-up affect my liquidity if I buy shares on opening day?
A: The lock-up applies only to pre-IPO shareholders and employees, not to shares purchased on the secondary market after the IPO prices.

Q: What is the tax treatment if I sell Latigo shares within 30 days of purchase?
A: Short-term capital gains apply at your ordinary income rate, 37% for high earners, with no qualified dividend treatment available.

Q: How much of a $1M allocation can I offset with tax-loss harvesting if the position declines 40%?
A: A $400K loss offsets $400K in short-term gains elsewhere, saving $148K in taxes at the 37% rate, netting a $252K after-tax loss.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax Capital Gains to model your exact outcome across price range scenarios and holding period assumptions before the final S-1 amendment publishes.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Consult a qualified tax advisor or investment professional before making any investment decisions.

#IPO #Biotech #TaxPlanning #CapitalGains #PortfolioConstruction

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY